Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.669 % w/v - solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: water for injections; benzenesulfonic acid - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: water for injections; benzenesulfonic acid - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Kenya - English - Pharmacy and Poisons Board

reddys pharma limited off mombasa road, masai road nairobi - atracurium besilate bp - injection - atracurium besilate bp 10mg/ml - atracurium

United States - English - NLM (National Library of Medicine)

curium us llc - indium chloride in-111 (unii: 58td96h03i) (indium cation in-111 - unii:wjz06c0h8l) - indium cation in-111 10 mci in 1 ml - indium in 111 chloride sterile solution is indicated for radiolabeling prostascint preparations used for in vivo diagnostic imaging procedures. it is also indicated for radiolabeling zevalin preparations used for radioimmunotherapy procedures. please refer to the package insert for prostascint or zevalin for information on the final drug product. please refer to the package insert for prostascint or zevalin for this information on the final drug product.

United States - English - NLM (National Library of Medicine)

curium us llc - gallium chloride ga-67 (unii: a04b19o2b0) (gallium cation ga-67 - unii:99t03j52w0) - gallium cation ga-67 2 mci in 1 ml - gallium citrate ga 67 injection may be useful to demonstrate the presence and extent of hodgkin's disease, lymphoma, and bronchogenic carcinoma. positive gallium ga-67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. gallium citrate ga 67 injection may be useful as an aid in detecting some acute inflammatory lesions. none.

United States - English - NLM (National Library of Medicine)

curium us llc - oxidronate disodium (unii: h852yk87wp) (oxidronic acid - unii:71mr4v32ti) - oxidronate disodium 3.15 mg - technescan hdp tc 99m is a diagnostic skeletal imaging agent used to demonstrate areas of altered osteogenesis in adult and pediatric patients. none known. all procedures should be conducted using waterproof gloves. use shielded syringe during transport and administration of tc 99m solutions. - remove plastic disc from technescan hdp vial and cleanse top by swabbing with alcohol. note: if dose is for a single adult patient or for a pediatric patient, see unit dose preparation method below. - place vial in lead vial shield. add 3 to 6 ml of sodium pertechnetate tc 99m solution and secure with a fitted lead cover. in choosing the amount of tc 99m radioactivity to be used, the number of doses desired, the activity of each dose [recommended adult dose is 555 mbq (15 mci) with a range of 370 to 740 mbq (10 to 20 mci)] and radioactive decay must be taken into account. the recommended maximum amount of tc 99m radioactivity to be added to the vial is 11.1 gigabecquerels (300 mci). note: the contents of the vial are

United States - English - NLM (National Library of Medicine)

curium us llc - sodium iodide i-123 (unii: 29ukx3a616) (iodide ion i-123 - unii:98qpv8670c) - iodide ion i-123 100 uci - administration of sodium iodide i 123 capsules is indicated as a diagnostic procedure to be used in evaluating thyroid function and/or morphology. to date there are no known contraindications to the use of sodium iodide i 123 capsules.

United States - English - NLM (National Library of Medicine)

sandoz inc - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. risk summary the 10 ml cisatracurium besylate multiple-dose vials contain the preservative benzyl alcohol. therefore, if cisatracurium besylate is needed during pregnancy, consider using a benzyl alcohol-free formulation (i.e., 5 ml and 20 ml cisatracurium besylate single-dose vials). because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely. however, adverse reactions have occurred in premature neonates and low birth weight infants who received intravenously administered benzyl alcohol-containing drugs [see contraindications (4), warnings and precautions (5.2), and use in specific populations (8.4)] . there are no available clinical trial data on cisatracurium use in pregnancy to evaluate a drug associated risk of major birth defects, miscarria